Supplementary Materials and Methods from Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
Elena Ardini(Nerviano Medical Sciences), Arturo Galvani(Nerviano Medical Sciences), Wei Ge(People's Liberation Army No. 150 Hospital), Cristina Ponti(University of Milan), Dario Ballinari(Nerviano Medical Sciences), Paola Magnaghi(Nerviano Medical Sciences), Paolo Orsini(Nerviano Medical Sciences), Nilla Avanzi(Nerviano Medical Sciences), Daniele Donati(Nerviano Medical Sciences), Anna Degrassi(Nerviano Medical Sciences), Maria Menichincheri(Nerviano Medical Sciences), Roberta Bosotti(Human Technopole), Tiziano Bandiera(Nerviano Medical Sciences), Marina Ciomei(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia), Gemma Texidó(Nerviano Medical Sciences), Luca Mologni(Azienda Ospedaliera San Gerardo), Patrizia Banfi(Nerviano Medical Sciences), Eduard Felder, Daniele Casero(Nerviano Medical Sciences), Maria Beatrice Saccardo(Nerviano Medical Sciences), Enrico Pesenti, Jason B. Harris(Harvard University), Gang Li(Qiqihar Medical University), David J. Anderson(Pacific Northwest National Laboratory), Jean‐Michel Vernier(ViaCyte (United States)), Romana Pulci(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences)
Cited by 0
Related Papers
Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
NK Cells and Cancer
|The Journal of Immunology|2007|296
Infusion of Mesenchymal Stem Cells and Rapamycin Synergize to Attenuate Alloimmune Responses and Promote Cardiac Allograft Tolerance
|American Journal of Transplantation|2009|281
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205